“…5,[11][12][13] Furthermore, biomarkers may also be a means to predict disease progression and optimize individual treatments. 14,15 Abbreviations: ASPN, asporin; AUGN, augurin; Col, collagen; pN Col III, N-propeptide collagen type III; CILP1, cartilage intermediate layer protein 1; CILP2, cartilage intermediate layer protein 2; CHAD, chondroadherin; COMP, cartilage oligomeric matrix protein; CHADL, chondroadherin link protein; CSPG2, versican core protein; COBA2, collagen alpha-2 (XI) chain; DERM, dermatopontin; ECM, extracellular martix; FMOD, fibromodulin; Fx, fracture; FINC, fibronectin; GAGs, glycosaminoglycans; HPLN, hyaluronan and PG link protein; HTRA1, serine protease HTRA1; LC, liquid chromatography; LUM, lumican; MS, mass spectrometry; MRM, multiple reaction monitoring; MATN1, matrilin-1; MATN3, matrilin-3; MIME, mimecan; MGP, matrix Gla protein; OA, osteoarthritis; OMD, osteomodulin; OSTP, osteopontin; PGs, proteoglycans; PGCA, aggrecan core protein; PGS1, biglycan; PGS2, decorin; PRG4, lubricin; PRELP, prolargin; PGBM, basement membrane specific heparin sulfate PG core protein; TSP1, thrombospondin-1; TSP4, thrombospondin-4; SLRPs, small leucine rich repeat proteoglycans; TENA, tenascin-C; TENX, tenascin-X; TGF-b, Transforming growth factor-beta Patrik The aim of this study was to explore candidate proteins in early events of osteoarthritic cartilage which may predict development of OA. We used targeted proteomics and liquid chromatography coupled with mass spectrometry LC-MS.…”